ProText Mobility, Inc. (TXTM)
USD 0.0
(-12.5%)
USD 0.0
(-12.5%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 15 Million USD | -0.0% |
| 2022 | 15 Million USD | 8724.9% |
| 2021 | 170 Thousand USD | -16.42% |
| 2020 | 203.39 Thousand USD | -66.29% |
| 2019 | 603.39 Thousand USD | -76.82% |
| 2018 | 2.6 Million USD | -0.02% |
| 2017 | 2.6 Million USD | 2.79% |
| 2016 | 2.53 Million USD | 0.0% |
| 2013 | 4541.00 USD | 48.93% |
| 2012 | 3049.00 USD | -98.63% |
| 2011 | 222.37 Thousand USD | -25.16% |
| 2010 | 297.12 Thousand USD | -29.32% |
| 2009 | 420.34 Thousand USD | 41.6% |
| 2008 | 296.86 Thousand USD | -49.16% |
| 2007 | 583.95 Thousand USD | -76.41% |
| 2006 | 2.47 Million USD | 15.75% |
| 2005 | 2.13 Million USD | -4.86% |
| 2004 | 2.24 Million USD | 481.67% |
| 2003 | 386.47 Thousand USD | -5.06% |
| 2002 | 407.08 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 15 Million USD | -0.0% |
| 2023 Q3 | 15.17 Million USD | -0.01% |
| 2023 Q2 | 15.17 Million USD | 0.01% |
| 2023 Q1 | 15.17 Million USD | -0.01% |
| 2023 Q4 | 15 Million USD | -1.11% |
| 2023 FY | 15 Million USD | -0.0% |
| 2022 Q1 | 203.39 Thousand USD | 0.0% |
| 2022 Q4 | 15.17 Million USD | 7421.3% |
| 2022 FY | 15 Million USD | 8724.9% |
| 2022 Q3 | 201.72 Thousand USD | 0.0% |
| 2021 Q3 | 203.39 Thousand USD | 0.0% |
| 2021 FY | 170 Thousand USD | -16.42% |
| 2021 Q4 | 203.39 Thousand USD | 0.0% |
| 2021 Q2 | 203.39 Thousand USD | 0.0% |
| 2021 Q1 | 203.39 Thousand USD | 0.0% |
| 2020 FY | 203.39 Thousand USD | -66.29% |
| 2019 FY | 603.39 Thousand USD | -76.82% |
| 2018 FY | 2.6 Million USD | -0.02% |
| 2017 FY | 2.6 Million USD | 2.79% |
| 2016 FY | 2.53 Million USD | 0.0% |
| 2014 Q3 | 20.49 Thousand USD | -20.04% |
| 2014 Q1 | 82.66 Thousand USD | 1720.46% |
| 2014 Q2 | 25.63 Thousand USD | -68.99% |
| 2013 Q3 | 16.58 Thousand USD | 1.76% |
| 2013 FY | 4541.00 USD | 48.93% |
| 2013 Q1 | 4332.00 USD | 42.08% |
| 2013 Q4 | 4541.00 USD | -72.61% |
| 2013 Q2 | 16.29 Thousand USD | 276.18% |
| 2012 FY | 3049.00 USD | -98.63% |
| 2012 Q4 | 3049.00 USD | -97.54% |
| 2012 Q3 | 123.95 Thousand USD | -18.63% |
| 2012 Q2 | 152.32 Thousand USD | -32.24% |
| 2012 Q1 | 224.79 Thousand USD | 1.09% |
| 2011 FY | 222.37 Thousand USD | -25.16% |
| 2011 Q4 | 222.37 Thousand USD | -31.52% |
| 2011 Q3 | 324.72 Thousand USD | 9.44% |
| 2011 Q2 | 296.72 Thousand USD | -6.74% |
| 2011 Q1 | 318.15 Thousand USD | 7.08% |
| 2010 FY | 297.12 Thousand USD | -29.32% |
| 2010 Q1 | 372.94 Thousand USD | -11.28% |
| 2010 Q2 | 410.68 Thousand USD | 10.12% |
| 2010 Q3 | 363.12 Thousand USD | -11.58% |
| 2010 Q4 | 297.12 Thousand USD | -18.18% |
| 2009 Q3 | 1.44 Million USD | 303.09% |
| 2009 FY | 420.34 Thousand USD | 41.6% |
| 2009 Q4 | 420.34 Thousand USD | -70.95% |
| 2009 Q2 | 358.98 Thousand USD | -13.67% |
| 2009 Q1 | 415.82 Thousand USD | 40.07% |
| 2008 Q4 | 296.86 Thousand USD | 17.45% |
| 2008 Q2 | 544.29 Thousand USD | -13.47% |
| 2008 Q1 | 628.99 Thousand USD | 7.71% |
| 2008 FY | 296.86 Thousand USD | -49.16% |
| 2008 Q3 | 252.76 Thousand USD | -53.56% |
| 2007 Q2 | 2.25 Million USD | -15.21% |
| 2007 Q1 | 2.65 Million USD | 7.33% |
| 2007 FY | 583.95 Thousand USD | -76.41% |
| 2007 Q4 | 583.95 Thousand USD | -75.18% |
| 2007 Q3 | 2.35 Million USD | 4.45% |
| 2006 Q3 | 2.45 Million USD | -1.39% |
| 2006 FY | 2.47 Million USD | 15.75% |
| 2006 Q2 | 2.49 Million USD | 2.7% |
| 2006 Q1 | 2.42 Million USD | 13.49% |
| 2006 Q4 | 2.47 Million USD | 0.71% |
| 2005 Q3 | 3.98 Million USD | -4.27% |
| 2005 Q1 | 2.2 Million USD | -1.72% |
| 2005 FY | 2.13 Million USD | -4.86% |
| 2005 Q4 | 2.13 Million USD | -46.37% |
| 2005 Q2 | 4.16 Million USD | 88.58% |
| 2004 Q4 | 2.24 Million USD | -5.37% |
| 2004 Q2 | 2.39 Million USD | 109.91% |
| 2004 Q1 | 1.14 Million USD | 195.11% |
| 2004 FY | 2.24 Million USD | 481.67% |
| 2004 Q3 | 2.37 Million USD | -0.77% |
| 2003 FY | 386.47 Thousand USD | -5.06% |
| 2003 Q2 | 169.52 Thousand USD | -14.41% |
| 2003 Q4 | 386.47 Thousand USD | 153.2% |
| 2003 Q3 | 152.63 Thousand USD | -9.96% |
| 2003 Q1 | 198.06 Thousand USD | 0.0% |
| 2002 FY | 407.08 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 10.55 Million USD | -42.144% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1846.661% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -2617.132% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -3021.759% |
| Qrons Inc. | 420.00 USD | -3571764.286% |
| Rebus Holdings, Inc. | 5000.00 USD | -299936.6% |
| Skye Bioscience, Inc. | 11.94 Million USD | -25.639% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 88.479% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 46.315% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -2082.129% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -666.107% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -649329.87% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 61.382% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -107.788% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -19547.733% |
| SQZ Biotechnologies Company | 107.18 Million USD | 86.004% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -947.59% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -20630.781% |
| Mesoblast Limited | 667.9 Million USD | 97.754% |
| Marizyme, Inc. | 22.01 Million USD | 31.857% |
| Genus plc | 1.02 Billion USD | 98.542% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1004.413% |
| Pharming Group N.V. | 462.85 Million USD | 96.759% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -352.815% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -2906.144% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -2292.636% |
| ContraFect Corporation | 20.67 Million USD | 27.454% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -3743.017% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -3825.362% |
| IMV Inc. | 31.33 Million USD | 52.123% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -261.837% |
| MultiCell Technologies, Inc. | 126.22 USD | -11885361.892% |
| ONE Bio Corp. | 70.08 Million USD | 78.595% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -1496.468% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 88.326% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -3374.946% |
| Q BioMed Inc. | 3.51 Million USD | -326.732% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 57.356% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -5641.734% |
| Biomind Labs Inc. | 73.81 Thousand USD | -20222.451% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 96.639% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -935.435% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 50.019% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -446.249% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -476.285% |
| GB Sciences, Inc. | 103.44 Thousand USD | -14402.649% |
| Alpha Cognition Inc. | 2.45 Million USD | -511.778% |
| HST Global, Inc. | 1526.00 USD | -982981.913% |
| CSL Limited | 38.02 Billion USD | 99.961% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1418.455% |
| Halberd Corporation | 10.13 Thousand USD | -147978.472% |
| Enzolytics Inc. | 361.7 Million USD | 95.852% |
| Agentix Corp. | 261.39 Thousand USD | -5639.208% |
| Resverlogix Corp. | 8.11 Million USD | -84.865% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -698.871% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.67% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 68.551% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -2245.297% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -65752.377% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -67.634% |
| AVAX Technologies, Inc. | 7.37 Million USD | -103.355% |
| Zenith Capital Corp. | 7410.00 USD | -202353.846% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.557% |
| Ember Therapeutics, Inc. | 184.00 USD | -8153068.478% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -4561.762% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -5639.823% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1516.644% |
| Kadimastem Ltd | 2.3 Million USD | -551.098% |
| Helix BioMedix, Inc. | 3.02 Million USD | -395.914% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 71.534% |
| BioStem Technologies, Inc. | 14.56 Million USD | -3.032% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -26175.668% |
| LadRx Corporation | 2.3 Million USD | -550.026% |
| Cell Source, Inc. | 195.17 Thousand USD | -7586.506% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -4142.395% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -4142.395% |
| NovAccess Global Inc. | 62.24 Thousand USD | -24000.1% |
| Affymax, Inc. | 7.44 Million USD | -101.556% |
| Itoco Inc. | 1.4 Million USD | -971.504% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -15582.94% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -14052.67% |
| Mobile Lads Corp. | 52.00 USD | -28849573.077% |
| CytoDyn Inc. | 11.13 Million USD | -34.715% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -10392.845% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -83802.852% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -3791.818% |
| SYBLEU INC | 330.46 Thousand USD | -4439.571% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -3564.148% |
| International Stem Cell Corporation | 5.39 Million USD | -178.327% |
| Bioxytran, Inc. | 137.63 Thousand USD | -10799.483% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 9.513% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -18889.658% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -1634.963% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -99.572% |
| Neutra Corp. | 2851.00 USD | -526095.37% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 53.707% |
| PureTech Health plc | 693.97 Million USD | 97.838% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -85.871% |
| IXICO plc | 15.84 Million USD | 5.315% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -81.138% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 85.481% |
| CSL Limited | 38.02 Billion USD | 99.961% |
| Cellectis S.A. | 333.99 Million USD | 95.508% |